FDA approves OraQuick for HIV-1 and HIV-2 screenings
March 26 2004 12:00 AM ET
The Food and Drug Administration on Tuesday approved OraSure Technologies' rapid HIV antibody test for simultaneous screening for infection by both HIV-1 and HIV-2 subtypes of the virus. The test had previously been approved only to screen for HIV-1 infection, the strain of the virus most common in the United States. HIV-2 is common in West Africa. The combined screening allows for "broader detection, treatment, and prevention of HIV/AIDS," particularly in urban areas of the United States and in foreign countries, according to a press release from the company. The test can screen blood samples from finger sticks and venipuncture for HIV antibodies and produce results in about 20 minutes. The company is currently seeking FDA approval for the test to screen for HIV-1 and HIV-2 in oral fluids and blood plasma samples
- Another Lap for Michael Phelps’s Self-Proclaimed Girlfriend
- Texas AG: Same-Sex Couples' Request to Marry 'Untimely, Out of Order'
- Meet This Year's 'Prime Time 25'
- #TBT: They Died in the Closet
- STUDY: Gay Sex Helps Humans Bond and Survive
- PHOTOS: Explore Genderqueer and Other Genders Beyond the Binary